Last updated: March 22, 2026
What is Darvocet-N 50?
Darvocet-N 50 is a combination medication containing acetaminophen (650 mg) and propoxyphene napsylate (50 mg). It was prescribed for pain relief. The drug was marketed primarily in the United States by Abbott Laboratories. Its use declined following safety concerns, leading to market withdrawal.
Regulatory History and Market Withdrawal
The Food and Drug Administration (FDA) issued an advisory in 2010, recommending against the use of propoxyphene due to risks of cardiac toxicity and overdose. Abbott Laboratories voluntarily withdrew Darvocet-N 50 from the U.S. market in November 2010. This decision ended its legal marketing and sales in the U.S.
Market Dynamics
Pre-Withdrawal Market Position
Prior to withdrawal, Darvocet-N 50 was a common analgesic. Its market included:
- Therapeutic segment: Mild to moderate pain relief.
- Competition: Other combination analgesics with acetaminophen like Darvocet, Percocet, and Tylenol #3.
- Market size: The analgesic market in the U.S. was estimated at around $4-5 billion annually (IQVIA, 2010). Darvocet-N held approximately 1-2% market share at its peak, translating to an annual revenue of around $50 million.
Post-Withdrawal Market Impact
The withdrawal reduced the available options for this specific class. The impact:
- Shifted prescriptions to alternative opioids and non-opioid analgesics.
- Reduced generic sales and formulations, especially for propoxyphene-based compounds.
Market Shift and Opportunities
- Shift to opioids: Physicians increased prescribing of drugs like tramadol, hydrocodone, and oxycodone.
- Generic and biosimilar prospects: Limited due to the withdrawal of the original formulation.
- Potential for reformulation: No known plans for reintroduction leveraging newer, safer compounds.
Market Recovery and Future Outlook
Re-entry of propoxyphene-containing drugs like Darvocet-N 50 is unlikely. Regulatory restrictions preclude return unless reformulated with safety modifications. The analgesic market continues to grow, driven by aging populations and chronic pain prevalence, but the specific market segment for Darvocet-N 50 remains closed.
Financial Trajectory Analysis
| Year |
Estimated Revenue |
Market Share |
Notes |
| 2005 |
$55 million |
~1.2% |
Peak sales, high prescription volume |
| 2010 |
$45 million |
~1% |
Decline, approaching market withdrawal |
| Post-2010 |
$0 |
0% |
Complete withdrawal from market |
- Pre-2010 sales: Sustained revenue streams, with annual decline from 2005 onward.
- Post-2010: No legal sales; potential for black market or off-label use but negligible.
Legal and Regulatory Considerations
- The FDA's 2010 advisory specifically targeted propoxyphene products.
- Abbott's voluntary withdrawal exemplifies compliance.
- Future prospects hinge on reformulation or new safety data.
Competitive Landscape
| Company |
Product Alternatives |
Status |
| Purdue Pharma |
OxyContin, Percocet |
Dominant opioid analgesics |
| Mallinckrodt |
Tramadol, acetaminophen combinations |
Expanded non-opioid options |
| Teva |
Generic acetaminophen-combination analgesics |
Increased generic competition |
Closing of Darvocet-N 50 marks the end of a product initially contributing to the analgesic market, with future prospects limited due to regulatory constraints.
Key Takeaways
- Darvocet-N 50 was withdrawn in 2010 after FDA safety concerns.
- The drug occupied a small but significant segment of the analgesic market before withdrawal.
- Market dynamics shifted toward other opioids and NSAIDs with the withdrawal.
- Recovery, re-entry, or reformulation appears improbable under current regulations.
- The overall analgesic market continues to grow, unaffected by Darvocet-N 50's absence.
FAQs
1. Will Darvocet-N 50 ever return to the market?
Unlikely due to regulatory bans and safety issues. Reformulation would require new safety data and regulatory approval.
2. What replaced Darvocet-N 50 in pain management?
Prescription shifts moved toward safer NSAIDs, acetaminophen-based drugs, and newer opioids like tramadol and hydrocodone.
3. Are there generic versions still available worldwide?
No. The withdrawal was specific to the U.S. market. Other countries may have different regulations.
4. Could off-label use or illicit markets utilize Darvocet-N 50?
Potential exists but negligible, as official sales ceased following withdrawal.
5. How does the regulatory environment affect similar combination drugs?
Increased scrutiny post-2010 led to tighter regulations, especially for opioid and CNS-active agents. Future approvals depend on demonstrated safety profiles.
References
[1] IQVIA. (2010). U.S. Prescription Drug Market Data.
[2] FDA. (2010). FDA Advisory on Propoxyphene.
[3] Abbott Laboratories. (2010). Market Withdrawal Announcement.
